ArticleBioinformation2026
Comparative histological assessment of p53, Ki-67 and EGFR in oral squamous cell carcinoma grading and prognostication.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Primary central nervous system lymphoma and tumefactive demyelinating lesions in multiple sclerosis: a retrospective observational cohort study.Frontiers in oncology · 2026Article
- Proteomic identification and histopathological validation of candidate biomarkers CA1, HBB, Torsin A, andFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) outcomes require molecular markers beyond histological grading for reliable prognostication. Therefore, it is of interest to assess p53, Ki-67 and EGFR expression via immunohistochemistry in 96 confirmed OSCC cases, correlating with grade, lymph node metastasis and stage. All markers showed significantly elevated expression with advancing tumor grade (p53 in 78.1%, Ki-67 >50% in poorly differentiated tumors, EGFR in 71.9% of cases). Combined positivity offered superior correlation with lymph node metastasis (p<0.001) and advanced clinical stage versus individual markers. Integrated p53/Ki-67/EGFR assessment advances OSCC prognostication, warranting routine pathological use for enhanced clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.